Solid first half paves way for AMS' growth
This article was originally published in Clinica
Executive Summary
Woundcare specialist Advanced Medical Solutions (AMS) has posted its first ever profitable half-year results, after revenues of £7.9m ($15.9m) - a 22% increase on the same period the previous year - contributed to an overall pre-tax profit of £0.7m. The Cheshire, UK-based firm highlighted four key events as the main drivers behind the positive financial figures: the continued growth of its silver alginate business, the doubling of NHS trusts using its ActivHeal technology to more than 80, the successful US launch of its surgical skin sealant product, and the progression of its LiquiBand tissue adhesive towards US regulatory approval.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.